Peter J.K. van Meer

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment

Peter J.K. van Meer, Marlous Kooijman, Vera Brinks et al. · mAbs · 2013 · 130 citations · Full text

Pharmacy, Immunology, Clinical Immunology +15

A standardised framework to identify optimal animal models for efficacy assessment in drug development

Guilherme S. Ferreira, Désirée H. Veening-Griffioen, Wouter Boon et al. · PLoS ONE · 2019 · 68 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +14

The ability of animal studies to detect serious post marketing adverse events is limited

Peter J.K. van Meer, Marlous Kooijman, Christine C. Gispen‐de Wied et al. · Regulatory Toxicology and Pharmacology · 2012 · 64 citations · Full text

Pharmacy, Marketing, Pharmacovigilance +10

Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease

Désirée H. Veening-Griffioen, Guilherme S. Ferreira, Peter J.K. van Meer et al. · European Journal of Pharmacology · 2019 · 60 citations · Full text

Medicine, Animal Sciences, Dementia +16

How institutional logics hamper innovation: The case of animal testing

Marlous Kooijman, Marko P. Hekkert, Peter J.K. van Meer et al. · Technological Forecasting and Social Change · 2017 · 28 citations · Full text

Management, Innovation Management, Organization Studies +12